Intracerebral hemorrhage is the sudden burst of blood into the brain tissue itself.
It causes sudden onset of focal neurological deficit.
The focal neurologic findings are related to the anatomic location, size and speed of development of intracerebral hemorrhage.
Neurological deficit usually progresses over a minute to an hour.
Rapid recognition and diagnosis of intracerebral hemorrhage are essential because of its frequently rapid progression.
A multicenter trial to investigate whether antithrombotic therapy can be initiated in atrial fibrillation (AF) patients who have survived an intracerebral haemorrhage (ICH) can be done, based on the results of the phase II feasibility trial NASPAF-ICH* presented at the 2020 International Stroke Conference (ISC).
Asian ischaemic stroke patients with small and fragile cerebral vessels, as evidenced by the presence of multiple cerebral microbleeds (CMBs), may fare better with cilostazol than aspirin, as the former proves more effective at preventing cerebral haemorrhages especially when administered before white matter changes become extensive, according to the results of a subgroup analysis of the PICASSO* trial.
Restarting antiplatelet therapy in survivors of intracranial haemorrhage (ICH)-related stroke is safe without raising their risk of a recurrent ICH, contrary to the commonly perceived risk of a recurrence with an antithrombotic drug, the RESTART* trial has shown.
A dual antiplatelet therapy (DAPT) of aspirin and clopidogrel significantly prevented the recurrence of major ischaemic events within 90 days following a minor stroke compared with aspirin alone, albeit this comes at the cost of increased major bleeding risk, according to the POINT* study.
Real-world studies on patients with atrial fibrillation (AF) show that dabigatran is safe with low bleeding and stroke rates when used for long term (over 2 years) or used continuously in patients undergoing cardiovascular (CV) interventions, according to phase II results of the prospective, observational, global registry programme GLORIA-AF* presented at the EHRA 2018 Annual Congress.
Combining the anticoagulant rivaroxaban with aspirin reduces the risk of ischaemic stroke by almost half without a significant increase in the risk of intracerebral haemorrhage (ICH) or haemorrhagic transformation compared with aspirin alone in patients with stable coronary artery disease (CAD), according to new data from the COMPASS* study presented at ISC 2018.
The traditional medicinal herbs ginseng, dong-quai, and turmeric do not appear to affect platelet aggregation and increase bleeding risk when used alone or together with aspirin, despite the belief that these herbs have “blood-activating” properties in traditional medicine theory, a recent study shows.
Idarucizumab, a dabigatran-reversing humanized monoclonal antibody fragment, rapidly, completely, and durably reversed the anticoagulant effect of dabigatran in elderly patients with life-threatening bleeding or undergoing invasive medical interventions, according to a full cohort analysis of the RE-VERSE AD* study presented at the ISTH 2017 Congress in Berlin, Germany.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Cardiology - Malaysia digital copy today!
Blood pressure (BP) control can be best achieved with a multilevel, multicomponent approach involving team-based care with physician- and non-physician-led interventions, as well as patient-level strategies, according to findings of a meta-analysis.
Not only are probiotics healthy for the gut, they may also be good for the waistline. A recent study shows that supplementation with the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 (Ba8145) improves anthropometric adiposity measures such as waist circumference, body mass index (BMI), and visceral fat area in abdominally obese individuals, particularly in women.